Valeo Financial Advisors LLC increased its stake in Hill-Rom Holdings, Inc. (NYSE:HRC) by 18,894.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,924 shares of the medical technology company’s stock after purchasing an additional 95,419 shares during the quarter. Hill-Rom makes up 1.1% of Valeo Financial Advisors LLC’s investment portfolio, making the stock its 14th largest holding. Valeo Financial Advisors LLC’s holdings in Hill-Rom were worth $8,065,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Arizona State Retirement System increased its stake in Hill-Rom by 2.5% in the 3rd quarter. Arizona State Retirement System now owns 47,151 shares of the medical technology company’s stock worth $4,451,000 after purchasing an additional 1,136 shares in the last quarter. W.E. Donoghue & Co. LLC increased its stake in Hill-Rom by 101.9% in the 3rd quarter. W.E. Donoghue & Co. LLC now owns 10,466 shares of the medical technology company’s stock worth $988,000 after purchasing an additional 5,281 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Hill-Rom by 52.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 20,406 shares of the medical technology company’s stock worth $1,927,000 after purchasing an additional 6,990 shares in the last quarter. Creative Planning grew its stake in Hill-Rom by 4.0% during the 3rd quarter. Creative Planning now owns 20,694 shares of the medical technology company’s stock valued at $1,954,000 after acquiring an additional 794 shares in the last quarter. Finally, First Citizens Bank & Trust Co. purchased a new position in Hill-Rom during the 3rd quarter valued at about $269,000. 81.01% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on HRC shares. ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Barclays started coverage on Hill-Rom in a research note on Monday, October 15th. They set an “equal weight” rating and a $95.00 target price on the stock. Raymond James lifted their target price on Hill-Rom from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, July 30th. Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a research note on Wednesday, August 1st. Finally, Morgan Stanley lifted their target price on Hill-Rom from $95.00 to $100.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Hill-Rom presently has an average rating of “Hold” and an average price target of $99.44.
NYSE:HRC opened at $90.37 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.18 and a current ratio of 1.58. Hill-Rom Holdings, Inc. has a fifty-two week low of $75.21 and a fifty-two week high of $98.96. The stock has a market cap of $5.51 billion, a price-to-earnings ratio of 23.41, a price-to-earnings-growth ratio of 1.17 and a beta of 0.89.
Hill-Rom (NYSE:HRC) last released its earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.12. The company had revenue of $759.20 million for the quarter, compared to analysts’ expectations of $750.90 million. Hill-Rom had a return on equity of 20.54% and a net margin of 8.19%. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.32 EPS. As a group, equities analysts forecast that Hill-Rom Holdings, Inc. will post 4.64 earnings per share for the current fiscal year.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Further Reading: How Do You Calculate Return on Equity (ROE)?
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.